Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

204 results about "Doxorubicin Hydrochloride" patented technology

The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.

Preparation method and application of Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere

InactiveCN105832699AGuarantee a high degree of decentralizationGood monodispersityOrganic active ingredientsMaterial nanotechnologyDrug release rateYolk
The invention provides a preparation method and application of a Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere. The preparation method comprises the following steps: preparing Fe2O3 nanoparticles by using a solvothermal method; under the condition that no surfactant is added and TEOS is used as a silicon source, preparing a Fe3O4@SiO2 composite microsphere with controllable morphology under mild conditions by using a combination of a template method and a hydrothermal method; corroding the Fe3O4@SiO2 composite microsphere with hydrochloric acid with a certain concentration so as to obtain a Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere; and carrying out reduction so as to prepare the Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere with superparamagnetism. The prepared Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere has a specific surface area of 173 m<2>/g and drug loading capacity of 139 mg/g; and with doxorubicin hydrochloride as a drug model, the Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere has a drug release rate of as high as 68.4% within 72 h in a PBS buffer solution with a pH value of 7.4, so the composite microsphere presents good slow drug release performance.
Owner:HENAN UNIVERSITY

Preparation method of hepatoma carcinoma cell targeted molybdenum disulfide drug-loaded nano tablets

The invention provides a preparation method of a hepatoma carcinoma cell targeted molybdenum disulfide drug-loaded nano tablets. The preparation method comprises following steps: step 1, molybdenum disulfide nano tablets are obtained via hydro-thermal synthesis; step 2, the molybdenum disulfide nano tablets are added into a gelatin solution, and gelatinized molybdenum disulfide nano tablets are obtained via sufficient reaction; step 3, lactobionic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and N-hydroxy succinimide are weighed and added into the gelatinized molybdenum disulfide nano tablets so as to obtain lactobionic acid modified molybdenum disulfide nano tablets; and step 4, a doxorubicin hydrochloride aqueous solution is prepared, and the lactobionic acid modified molybdenum disulfide nano tablets obtained via step 3 are added into the doxorubicin hydrochloride aqueous solution, an obtained mixture is stirred for 8 to 24h under vacuum conditions, and is subjected to centrifugalization and washing so as to obtain the hepatoma carcinoma cell targeted molybdenum disulfide drug-loaded nano tablets via collecting. The hepatoma carcinoma cell targeted molybdenum disulfide drug-loaded nano tablets can be used for photothermal therapy and CT imaging, and can be used for realizing combination of diagnosis and treatment of hepatoma carcinoma.
Owner:DONGHUA UNIV

Method for preparing stable albumin nano-particles by virtue of thermal denaturation

The invention belongs to the field of preparation of biological medical materials, and relates to a method for preparing stable albumin nano-particles by virtue of thermal denaturation. The method comprises the following steps: (1) adding vanillic aldehyde or an analogue thereof to form intermolecular disulfide bonds by virtue of inter-reaction of free sulfhydryl groups on albumin molecules under a heating condition; (2) enabling amino groups inside and among molecules to react with carboxyl so as to form amido bonds; and (3) enabling amino groups on the albumin molecules to react with aldehyde groups on vanillic aldehyde or the analogue thereof to form chemical bonds of Schiff base and the like so as to form stable nano-particles in an aqueous solution. Any organic solvent is not introduced during preparation, so that the prepared nano-particles are safe and nontoxic, and can well entrap antitumor drugs including paclitaxel, doxorubicin hydrochloride and the like. Moreover, the carrier has an oxidation reduction response in a tumor cell internal environment, and can open disulfide bonds to release drugs under the action of reducing glutathione in cells. The method provided by the invention is simple in process, convenient to operate and suitable for industrial mass production.
Owner:CHINA PHARM UNIV

Doxorubicin hydrochloride-docetaxel or paclitaxel liposome preparation and preparation method thereof

ActiveCN103622912ALess toxic and side effectsIncreased therapeutic functionOrganic active ingredientsAntineoplastic agentsSide effectFreeze-drying
The invention adopts the technical scheme that a doxorubicin hydrochloride-docetaxel or paclitaxel liposome preparation is provided. According to the technical scheme adopted by the invention, a water-soluble medicine and a fat-soluble medicine are encapsulated by liposome simultaneously; the water-soluble medicine is wrapped with the inner environment of the liposome; the fat-soluble medicine is wrapped between double layers of phospholipid membranes of the liposome; the water-soluble medicine is doxorubicin hydrochloride; and the fat-soluble medicine is docetaxel or paclitaxel. The doxorubicin hydrochloride-docetaxel or paclitaxel liposome preparation has the benefits that experiments prove that the toxic or side effect of the doxorubicin hydrochloride-docetaxel or paclitaxel liposome is obviously reduced and the anti-tumor therapy function of the doxorubicin hydrochloride-docetaxel or paclitaxel liposome is enhanced; the medicine encapsulation ratio of the liposome can reach 90% above; the result of the two-year stability experiment of the freeze-dried powder of the liposome at 2 to 8 DEG C below shows that the change rate of the average grain size is less than 6% and the change rate of the medicine encapsulation ratio is less than 5%, and shows excellent stability of the doxorubicin hydrochloride-docetaxel or paclitaxel liposome preparation.
Owner:常州金远药业制造有限公司

Enzymatic catalysis crosslinking reduction-responsive hyaluronic acid microgel and preparation method thereof

The invention discloses enzymatic catalysis crosslinking reduction-responsive hyaluronic acid microgel and a preparation method thereof. The hyaluronic acid microgel is prepared by taking sulfhydrylation hyaluronic acid as a raw material, taking horseradish peroxidase as a catalyst, taking tyramine hydrochloride as an enzymatic catalysis reaction substrate and combining the method that horseradish peroxidase is catalytically crosslinked with sulfydryl to generate a disulfide bond through an inverse emulsion method. The disulfide bond crosslinking structure in the microgel can be broken in the presence of reductive substances such as dithiothreitol, reductive glutathione hormone and L-cysteine, and then the good reduction responsiveness is given to the microgel. The hyaluronic acid microgel can achieve controlled release on the reduction responsiveness of loaded doxorubicin hydrochloride and can be applied to controlled release of tumor-targeted drugs. According to the preparation method, a crosslinking agent does not need to be additionally added into an inverse emulsion system to cure the microgel, the toxicity influence of the crosslinking agent is avoided, the biocompatibility of the microgel is guaranteed, the reaction conditions are mild, and the technological processes are simple.
Owner:NANCHANG UNIV

Doxorubicin hydrochloride loaded temperature-sensitive self-healing hydrogel and preparation method thereof

The invention relates to a doxorubicin hydrochloride loaded temperature-sensitive self-healing hydrogel and a preparation method thereof. The doxorubicin hydrochloride loaded temperature-sensitive self-healing hydrogel comprises chitosan, sodium beta-glycerophosphate, and polyethylene glycol with two ends respectively carrying a benzaldehyde group. The preparation method comprises the following steps: forming an imide bond with a self-healing performance through using a reaction of an amino group in the structure of chitosan and the benzaldehyde groups at two ends of the polyethylene glycol, combining the imide bond with chitosan / sodium beta-glycerophosphate temperature-sensitive gel, and loading doxorubicin hydrochloride into the obtained material through physical clathration to prepare the novel temperature-sensitive self-healing hydrogel administration system. The administration system is a liquid at room temperature, and rapidly gelates at a human body temperature after being injected to a tumor position in order to form a medicine reservoir ; and compared with traditional in situ gels, the temperature-sensitive self-healing hydrogel has the advantages of strong mechanical strength, realization of rapid self restoration under the action of outside force or tissue damages to avoid burst release of a medicine, further delay of release of the medicine and prolongation of the detention time of the medicine in the tumor position, medicine effect enhancement and reduction of toxic and side effects.
Owner:CHINA PHARM UNIV

Multi-functional bismuth selenide nanocomposite and preparation method and application thereof

The invention relates to the field of biomedicine, in particular to a multi-functional bismuth selenide nanocomposite and a preparation method and application thereof. The multi-functional bismuth selenide nanocomposite aims to solve the problems that the synthesis condition and process of the existing hyperthermia chemotherapy nano material are complex, the biological safety is poor, the drug loading capacity is low, the existing hyperthermia chemotherapy nano material is short of an appropriate imaging diagnosis function, the heat-light properties need to be improved, and the existing hyperthermia chemotherapy nano material is short of clinical experimental verification. The grain size of the multi-functional bismuth selenide nanocomposite is 50 nm to 200 nm, and the drug loading capacity for loading doxorubicin hydrochloride is 3% to 10%. The preparation method comprises a step 1 of preparing Bi2Se3 nanosheets; a step 2 of preparing Bi2Se3@PDA nano particle dispersion liquid; and a step 3 of preparing the multi-functional bismuth selenide nanocomposite. The multi-functional bismuth selenide nanocomposite serves as the hyperthermia chemotherapy nano material to be utilized in hyperthermia chemotherapy of a malignant tumor or serves as a CT imaging contrast agent to be utilized in CT imaging diagnosis of the malignant tumor.
Owner:HARBIN INST OF TECH

Doxorubicin hydrochloride light-controlled sustained-release liquid crystal gel preparation and preparation method thereof

The invention discloses a doxorubicin hydrochloride light-controlled sustained-release liquid crystal gel preparation and a preparation method thereof. The light-controlled sustained-release liquid crystal gel preparation is prepared from 15-40 wt% of phospholipid, 60-70 wt% of glyceride, 1-20 wt% of a cosolvent, 0.01-2 wt% of doxorubicin hydrochloride and 0.001-0.2 wt% of a photosensitizer. The doxorubicin hydrochloride light-controlled sustained-release liquid crystal gel preparation has the advantages of low viscosity, good fluidity, easiness in injection, rapidness in formation of the liquid crystal gel after being injected into or around a tumor or being placed in a post-operative tumor cavity, and realization of in-situ slow release of doxorubicin hydrochloride; and lights cause phase change of the liquid crystal gel and increase the drug release rate, and the preparation prolongs the drug action time, reduces the administration frequency, reduces the toxic and side effects of the drug, releases the drug as needed by adjusting the release of the drug through adjusting the illumination frequency or time according to the tumor pathological conditions of a patient, and greatly improves the bioavailability of the drug.
Owner:武汉百纳礼康生物制药有限公司

Graphene oxide surface-enhanced Raman scattering positioning drug carrier and preparation method thereof

The invention relates to a graphene oxide surface-enhanced Raman scattering positioning drug carrier and a preparation method thereof and one or more drugs carried by the graphene oxide surface-enhanced Raman scattering positioning drug carrier. The graphene oxide surface-enhanced Raman scattering positioning drug carrier utilizes a composite structure of graphene oxide and metal nanoparticles to carry a drug, utilizes surface-enhanced Raman scattering signals to trace a carrier position, and has a high drug carrying amount. A positively charged polymer modifies the surface of graphene oxide. The metal nanoparticles are gold nanorods. Raman molecules are adsorbed on the metal nanoparticles. The graphene oxide surface-enhanced Raman scattering positioning drug carrier solves the problem that the existing nano-drug carrier has a complex structure, a high synthesis cost and low efficiency and is difficult to industrialize. The preparation method comprises the following steps of graphene oxide preparation, graphene oxide-metal nanoparticle compound preparation, and graphene oxide drug carrier material preparation. The one or more carried drugs are selected from doxorubicin hydrochloride, 9-aminoacridine hydrochloride and hydroxycamptothecin.
Owner:SOUTHEAST UNIV

Doxorubicin hydrochloride-carrying natural polymer-poly(3-benzene acid acrylamide) composite nanospheres, manufacturing method and application thereof

The invention discloses natural polymer-poly(3-benzene acid acrylamide) composite nanospheres. The surfaces of the natural polymer-poly(3-benzene acid acrylamide) composite nanospheres are hydrophilic natural polymers; the interiors are hydrophobic poly(3-benzene acid acrylamide); the number average molecular weight of the natural polymer is in a range of between 2,000 and 100,000; the content ofthe natural polymer is 5 to 70 percent of the mass of the composite nanospheres; the number average molecular weight of the poly(3-benzene acid acrylamide) is in a range of between 1,000 and 10,000; the content of the poly(3-benzene acid acrylamide) is 30 to 95 percent of the mass of the composite nanospheres; and the average grain diameter of the composite nanospheres is of between 40 and 100 nanometers. The composite nanospheres of the invention have the characteristics of high biocompatibility and stable chemical properties. The composite nanospheres of the invention can be used as a medicament carrier, has a sustained-release effect, and can be used as a carrying agent in a boron neutron capture therapy. The invention also discloses a manufacturing method for the composite nanospheres.
Owner:NANJING UNIV

Doxorubicin hydrochloride-loaded self-healing hydrogel drug administration system

The invention discloses a doxorubicin hydrochloride-loaded self-healing hydrogel drug administration system and a preparation method thereof. The preparation method comprises the steps of oxidating pullulan into aldehyde-rich oxidated pullulan; by taking the oxidated pullulan, epsilon-polylysine, branched polyethyleneimine and doxorubicin hydrochloride as raw materials, performing Schiff base reaction in a water solution to form a dynamic imine bond cross-linked network, thus obtaining the self-healing hydrogel drug delivery system, wherein the doxorubicin hydrochloride is loaded into the system by two modes of dynamic imine bond cross linking and gel mesh adsorption. The preparation method is simple and easy to operate, the obtained hydrogel drug delivery system has good biocompatibility, biodegradability, temperature and pH sensitivity, self-sealing property and syringeability, and can be directly injected into a diseased region by tumor periphery injection drug administration without surgery implantation, thus greatly alleviating the pain of a patient, slowly releasing the doxorubicin hydrochloride in vivo, being beneficial to reducing of toxic and side effects of a drug, and achieving the aim of efficiently attenuating toxicity in a tumor treatment process.
Owner:FUZHOU UNIV

Preparation method of cell membrane microcapsule simultaneously loaded with chemotherapeutic drug and photodynamic therapeutic drug

The invention discloses a cell membrane microcapsule simultaneously loaded with a chemotherapeutic drug and a photodynamic therapeutic drug. Human cells are selected as a raw material for preparing the cell membrane microcapsule; the obtained cell membrane microcapsule is soaked into a digitonin solution to improve the permeability of cell membranes; a chemotherapeutic drug namely doxorubicin hydrochloride and a photodynamic therapeutic drug namely indocyanine green are added sequentially to ensure that the drugs are infiltrated into the cell membrane microcapsule; and calcium ions are used for sealing the cell membranes to obtain the cell membrane microcapsule simultaneously loaded with the chemotherapeutic drug and the photodynamic therapeutic drug. The cell membrane microcapsule can generate active oxygen under the irradiation of laser light of 808nm, and the active oxygen and the chemotherapeutic drug act together to kill tumor cells, so that the cell membrane microcapsule is expected to be used for tumor treatment. The preparation method of the cell membrane microcapsule disclosed by the invention is simple, convenient and controllable, is high in production efficiency and has good application prospects.
Owner:ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products